Practical discussion on switching studies and how this relates to managing lipids

Pozniak A , Gazzard B , Anderson J British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003; 4: 141

Katlama C , Fenske S , Gazzard B TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003; 4: 7986

Opravil M , Hirschel B , Lazzarin A A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 125160

Clumeck N , Goebel F , Rozenbaum W Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001; 15: 151726

Keiser PH , Sension MG , Dejesus E Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologie suppression, and simplifies treatment. BMC Infect Dis 2005; 5: 2

Walli RK , Michl GM , Bogner JR , Goebel FD . Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6: 41321

Martínez E , Arnaiz JA , Podzamczer D Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 103646

Maggiolo F , Ripamonti D , Ravasio L Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003; 37: 419

Ruiz L , Negredo E , Domingo P Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27: 22936

Barreiro P , Soriano V , Blanco F Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14: 80712

Negredo E , Cruz L , Paredes R Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34: 50410

Negredo E , Ribalta J , Paredes R Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16: 13839

Carr A , Hudson J , Chuah J HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 181122

Katlama C , Staszewski S , Cluck N Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable HIV-1 RNA: results of a prospective, randomised, multicentre, open-label study (DMP 006-027). Presented at XIII World AIDS Conference, Durban, June 2000; Abst LePeB7044

Martinez E , Romeu J , Garcia-Viego A An open randomised study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1 infected patients with lipodystrophy Presented at the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001; Abst 668

Becker S , Rachlis A , Gill J Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads - a prospective, randomized, multicentre, open-label study (DMP 049). Presented at 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 2001; Abst 20

van Leth F , Phanuphak P , Ruxrungtham K Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and laimivudine: a randomized open-label trial, the 2NN study. Lancet 2004; 363: 125363

Gulick R Phase III, randomized, double-blind comparison of 3 protease inhibitor-sparing regimens for initial treatment of HIV infection. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, July 2003; Abst 41

Staszewski S , Keiser P , Gathe J Comparison of antiviral response with abacavir/combivir versus indinavir/combivir in therapy-naive adults: results at 48 weeks (CNA3005). Presented at the 39th Interscience Conference on Antimir-crobial Agents and Chemotherpay, San Francisco, September 1999; Abst 505

Carr A , Workman C , Smith DE Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 20715

Martin A , Sith De , Carr A Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension study. AIDS 2004; 18: 102936

Dragsted UB , Gerstoft J , Pedersen C Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 trial. J Infect Dis 2003; 188: 63542

Cahn PE , Gatell JM , Squires K Atazanavur - a once-daily HIV protease inhibitor that does not casue dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care 2004; 3: 928

Johnson M , Grinsztejn B , Rodriguez C Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19: 15362

Walmsley S , Bernstein B , King M Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346: 203916

van Leth F , Phanuphak P , Ruxrungtham K Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and laimivudine: a randomized open-label trial, the 2NN Study Lancet 2004; 363: 125363